Thalia Therap. Share News (THAT)

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Light Science Technologies Holdings PLC - Derbyshire, England-based agriculture technology and fire protection company - Provides an update on trading within its Passive Fire Protection division following the acquisition of RLUK Injection Ltd in April. Says total injectaclad material supply orders secured since completion of the acquisition now amount to GBP885,000, progress which reflects the "strategic rationale" behind the acquisition. Chief Executive Simon Deacon says: "Securing [around] GBP885,000 of material supply orders within the first few months of ownership, alongside a growing installation pipeline, provides encouraging evidence that our strategy is gaining traction. We remain focused on supporting our installer network, converting opportunities within the project pipeline and building a scalable, higher-margin business within the PFP division."

----------

Tower Resources PLC - oil and gas company focused on Africa - Raises GBP400,000 via subscription at 0.016 pence per share as it expects approval in respect of the farm-out transactions with Prime Global Energies Ltd in Cameroon and Namibia "any day". A letter from the Namibian Ministry "is the final outstanding condition precedent for the completion of the Namibia farm-out, as other license holders have already received formal notifications of the farm-out and their pre-emption rights, which they have not taken up," the firm explains. In Cameroon, Tower has been informed that the file has moved up to the Office of the Presidency for action, with a covering letter from the Prime Minister. "This is necessary because the farm-out itself is contingent on a further extension of the initial exploration period of the Thali license, and as in the past, requires Presidential assent. So this process is also moving forward in the right way," the firm says. Given this progress, the firm considers it "prudent" to raise a modest amount of additional working capital, since even if both farm-out agreements are completed in the course of July, the company could still be waiting several more weeks for the funding that those agreements will provide. "We are pleased to be making progress on both approval processes, even though we wish they were already completed. It is important to remember that even a straight-forward farm-out proposal requires substantial government due diligence involving multiple departments, and we are grateful to all the individuals who have contributed to this process," the company says.

----------

Verici Dx PLC - Cardiff, Wales-based developer of advanced clinical diagnostics for organ transplants - Announces that it has received clinical laboratory certification from the New York State Department of Health Clinical Laboratory Evaluation Program. This means Verici Dx has now completed its full authorisation to provide laboratory testing services in all 50 US states and the District of Columbia, creating nationwide availability of the Tutivia test. "New York is one of the most active kidney transplant locations in the country, with more than 2,000 transplants performed in 2025, underscoring the importance of access to Tutivia for clinicians managing complex, high-acuity patients," it notes

Tutiva is an RNA-based blood test developed by Verici Dx that assesses the risk of acute cellular rejection in kidney transplant recipients. "Receiving certification and test approval from the NYSDOH not only expands access to Tutivia for transplant centres in the state but also provides independent validation of our laboratory and data science operations and clinical performance. This milestone ensures our ability to support clinicians nationwide with the predictive intelligence they need to proactively manage complex transplant cases," says Chief Executive Sara Barrington.

----------

Thalia Therapeutics PLC - biotechnology company developing innovative RNA therapeutics - Announces the acquisition of US-based Sanmirna Therapeutics Inc, which holds an exclusive licence for the intellectual property and know-how around miRisten, an anti-microRNA-126 for the treatment of acute myeloid leukaemia, for an initial GBP3.7 million. Deferred milestone payments may reach up to a further GBP13 million. "This is an exciting and transformative opportunity to accelerate our clinical-stage oncology pipeline and diversify our RNA therapeutics pipeline," says Chief Executive David Solomon. The deal will create a "materially stronger, more diversified business with enhanced prospects for short, medium, and long-term shareholder value creation," he says. In addition, raises GBP2.8 million via a placing and subscription of 0.6 pence per share.

----------

Cambridge Cognition Holdings PLC - brain health software provider based in Cambridge - Raises GBP2.5 million via a placing and subscription at 35.0 pence per share. In addition, plans to raise a further GBP500,000 via a retail offer at the same price. Proceeds will support the next phase of the company's development, focused on "expanding adoption of its digital cognitive assessment platform within healthcare and clinical settings and progressing towards a more scalable, commercially focused business model".

----------

Tullow Oil PLC - London-based oil and gas company - Announces a partial USD48 million repayment of its outstanding senior secured notes due 2028. Chief Financial Officer Richard Miller says: "This partial repayment of the notes has been enabled by our strong operational and financial performance in 2026. Being able to take this meaningful step only two months after closing the refinancing transaction is reflective of our disciplined approach to capital allocation and the quality of our assets. We continue to focus on deleveraging and exploring longer term refinancing and strategic options, underpinned by our enhanced value proposition."

----------

Greencoat Renewables PLC - Dublin-based renewable energy infrastructure investor - Plans to start a second EUR25 million share buyback, part of EUR100 million programme announced in March. This will follow the completion of the first EUR25 million tranche, which is expected in July. Aims to complete the second tranche by no later than the end of 2026. J&E Davy and RBC Europe Ltd will manage the second tranche.

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2026 Alliance News Ltd. All Rights Reserved.